DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1762)

Crohn's Disease | Landscape & Forecast | Disease Landscape & Forecast

Crohn's Disease | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The Crohn’s disease ( CD ) therapy market will continue to evolve over the next decade. The well-established tumor necrosis factor-alpha ( TNF -α) inhibitors (, Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) helped transform the treatment landscape, especially for patients with moderate to severe disease, despite their efficacy limitations (, patients lose response over time) and safety risks. Takeda’s Entyvio, a cell adhesion molecule ( CAM ) inhibitor, which launched in 2014, offered an alternative treatment, especially for patients refractory to TNF -α inhibitors. Most recently, the introduction of the first-in-class interleukin ( IL )-12/23 inhibitor, Janssen’s Stelara, has expanded physicians’ treatment armamentarium and will further intensify market competition. Emerging therapies include more-convenient formulations of current agents and drugs with novel mechanisms of action ( MOA s) (, Galapagos/Gilead’s filgotinib); these products, together with the increasing availability of biosimilar agents, will further complicate the treatment landscape.
What are key opinion leaders’ ( KOL s’) insights on current treatment options for CD (, Remicade, Humira, Inflectra/Remsima)? What factors drive their treatment decisions?
What has been/will be the impact of the newer, non- TNF biologics (, Janssen’s Stelara, Takeda’s Entyvio) on the CD treatment algorithm?
What is KOL s’ opinion of the emerging oral therapies (, Galapagos/Gilead’s filgotinib)? What impact will stem-cell therapies (, TiGenix/Takeda’s Cx-601) have on the CD market?
How will the market evolve over the next ten years? What impact will biosimilar agents have on the use of their branded counterparts and on the overall therapy market?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

  • Pub Date: November 2017
  • Author(s): Qinghui Yu

Request report

Related reports:
You may also be interested in: